{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T16:27:47Z","timestamp":1758040067463,"version":"3.44.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:00:00Z","timestamp":1573516800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.ahj.2019.11.004","type":"journal-article","created":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T19:36:21Z","timestamp":1573587381000},"page":"203-212","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Evolocumab treatment in patients with HIV and hypercholesterolemia\/mixed dyslipidemia: BEIJERINCK study design and baseline characteristics"],"prefix":"10.1016","volume":"220","author":[{"given":"Franck","family":"Boccara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Princy","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Caramelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Calmy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Antonio G.","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Bray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcoli","family":"Cyrille","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert S.","family":"Rosenson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2019.11.004_bb0005","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1161\/CIR.0000000000000695","article-title":"Characteristics, prevention, and management of cardiovascular disease in people living with HIV: a scientific statement from the American Heart Association","volume":"140","author":"Feinstein","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2019.11.004_bb0010","doi-asserted-by":"crossref","unstructured":"Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019;139:e1082-e143.","DOI":"10.1161\/CIR.0000000000000698"},{"key":"10.1016\/j.ahj.2019.11.004_bb0015","first-page":"2019","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","author":"Mach","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2019.11.004_bb0020","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1161\/CIRCULATIONAHA.117.033369","article-title":"Global burden of atherosclerotic cardiovascular disease in people living with HIV","volume":"138","author":"Shah","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2019.11.004_bb0025","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jacc.2012.06.063","article-title":"HIV and coronary heart disease: time for a better understanding","volume":"61","author":"Boccara","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2019.11.004_bb0030","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/S1473-3099(13)70271-8","article-title":"Metabolic disease in HIV infection","volume":"13","author":"Lake","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ahj.2019.11.004_bb0035","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/S2213-8587(15)00388-5","article-title":"Pathophysiology and management of cardiovascular disease in patients with HIV","volume":"4","author":"Nou","year":"2016","journal-title":"The lancet Diabetes & endocrinology"},{"key":"10.1016\/j.ahj.2019.11.004_bb0040","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/j.amjcard.2015.03.025","article-title":"A Systematic Review of the Usefulness of Statin Therapy in HIV-Infected Patients","volume":"115","author":"Feinstein","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2019.11.004_bb0045","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1002\/jcph.473","article-title":"Management of lipid disorders in patients living with HIV","volume":"55","author":"Myerson","year":"2015","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ahj.2019.11.004_bb0050","first-page":"6","article-title":"Evidence-based review of statin use in patients with HIV on antiretroviral therapy","volume":"8","author":"Chastain","year":"2017","journal-title":"J Clin Transl Endocrinol"},{"key":"10.1016\/j.ahj.2019.11.004_bb0055","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.010345","article-title":"Trends in utilization of statin therapy and contraindicated statin use in HIV-infected adults treated with antiretroviral therapy from 2007 through 2015","volume":"7","author":"Rosenson","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ahj.2019.11.004_bb0060","doi-asserted-by":"crossref","unstructured":"Burkholder GA, Muntner P, Zhao H, et al. Low-density lipoprotein cholesterol response after statin initiation among persons living with human immunodeficiency virus. J Clin Lipidol 2018;12:988\u201398 e5.","DOI":"10.1016\/j.jacl.2018.03.082"},{"key":"10.1016\/j.ahj.2019.11.004_bb0065","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/cit665","article-title":"Primary Care Guidelines for the Management of Persons Infected With HIV: 2013 Update by the HIV Medicine Association of the Infectious Diseases Society of America","volume":"58","author":"Aberg","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ahj.2019.11.004_bb0070","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2019.11.004_bb0075","doi-asserted-by":"crossref","unstructured":"Zanni MV, Stone LA, Toribio M, et al. Proprotein Convertase Subtilisin\/Kexin 9 Levels in Relation to Systemic Immune Activation and Subclinical Coronary Plaque in HIV. Open forum infectious diseases 2017;4:ofx227.","DOI":"10.1093\/ofid\/ofx227"},{"issue":"10","key":"10.1016\/j.ahj.2019.11.004_bb0080","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.jacc.2017.07.752","article-title":"Optimizing cholesterol treatment in patients with muscle complaints","volume":"70","author":"Rosenson","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2019.11.004_bb0085","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0195-668X(03)00114-3","article-title":"Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project","volume":"24","author":"Conroy","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2019.11.004_bb0090","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1161\/01.CIR.97.18.1837","article-title":"Prediction of coronary heart disease using risk factor categories","volume":"97","author":"Wilson","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2019.11.004_bb0095","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/aje\/kwh236","article-title":"Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review","volume":"160","author":"Austin","year":"2004","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.ahj.2019.11.004_bb0100","first-page":"14","article-title":"Trends in the risk of myocardial infarction among HIV-1-infected individuals relative to the general population in France: Impact of gender and immune status","volume":"e0210253","author":"Balde","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.ahj.2019.11.004_bb0105","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1093\/cid\/civ014","article-title":"Declining relative risk for myocardial infarction among HIV-positive compared with HIV-negative individuals with access to care","volume":"60","author":"Klein","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ahj.2019.11.004_bb0110","doi-asserted-by":"crossref","first-page":"e288","DOI":"10.1016\/S2352-3018(15)00077-6","article-title":"Time trends for risk of severe age-related diseases in individuals with and without HIV infection in Denmark: a nationwide population-based cohort study","volume":"2","author":"Rasmussen","year":"2015","journal-title":"The Lancet HIV"},{"key":"10.1016\/j.ahj.2019.11.004_bb0115","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ahj.2016.10.013","article-title":"Statin therapy and low-density lipoprotein cholesterol reduction in HIV-infected individuals after acute coronary syndrome: Results from the PACS-HIV lipids substudy","volume":"183","author":"Boccara","year":"2017","journal-title":"Am Heart J"},{"issue":"9","key":"10.1016\/j.ahj.2019.11.004_bb0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0203890","article-title":"Prevalence and trends of polypharmacy among HIV-positive and -negative men in the Multicenter AIDS Cohort Study from 2004 to 2016","volume":"13","author":"Ware","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ahj.2019.11.004_bb0125","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1161\/ATVBAHA.112.300125","article-title":"HIV disease activity as a modulator of lipoprotein(a) and allele-specific apolipoprotein(a) levels","volume":"33","author":"Enkhmaa","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ahj.2019.11.004_bb0130","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1194\/jlr.P084517","article-title":"Effect of antiretroviral therapy on allele-associated Lp(a) level in women with HIV in the Women's Interagency HIV Study","volume":"59","author":"Enkhmaa","year":"2018","journal-title":"J Lipid Res"},{"key":"10.1016\/j.ahj.2019.11.004_bb0135","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1161\/ATVBAHA.117.309137","article-title":"Lipoprotein(a) and HIV: Allele-Specific Apolipoprotein(a) Levels Predict Carotid Intima-Media Thickness in HIV-Infected Young Women in the Women's Interagency HIV Study","volume":"37","author":"Enkhmaa","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ahj.2019.11.004_bb0140","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1161\/CIRCRESAHA.118.313238","article-title":"Cholesterol-Lowering Agents","volume":"124","author":"Rosenson","year":"2019","journal-title":"Circ Res"},{"key":"10.1016\/j.ahj.2019.11.004_bb0145","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.009996","article-title":"Coronary Endothelial Dysfunction Is Associated With Elevated Serum PCSK9 Levels in People With HIV Independent of Low-Density Lipoprotein Cholesterol","volume":"7","author":"Leucker","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ahj.2019.11.004_bb0150","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41574-018-0110-5","article-title":"Inhibiting PCSK9\u2014biology beyond LDL control","volume":"15","author":"Stoekenbroek","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.ahj.2019.11.004_bb0155","series-title":"NCT03207945","article-title":"Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV). Identification No","author":"Hsue","year":"2017"},{"key":"10.1016\/j.ahj.2019.11.004_bb0160","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1172\/JCI97785","article-title":"Hypercholesterolemia induces T cell expansion in humanized immune mice","volume":"128","author":"Proto","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ahj.2019.11.004_bb0165","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1097\/QAD.0000000000001633","article-title":"Impact of protease inhibitors on circulating PCSK9 levels in HIV-infected antiretroviral-naive patients from an ongoing prospective cohort","volume":"31","author":"Boccara","year":"2017","journal-title":"AIDS"},{"key":"10.1016\/j.ahj.2019.11.004_bb0170","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.atherosclerosis.2019.02.015","article-title":"Clinical, behavioral and biomarker predictors of PCSK9 levels in HIV-infected patients na\u00efve of statin therapy: A cross-sectional analysis from the Swiss HIV cohort","volume":"284","author":"Gencer","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ahj.2019.11.004_bb0175","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002683","article-title":"HIV and Hepatitis C-Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent \"PCSK9-Lipid Paradox\"","volume":"5","author":"Kohli","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ahj.2019.11.004_bb0180","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/hep.22911","article-title":"PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression","volume":"50","author":"Labonte","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.ahj.2019.11.004_bb0185","doi-asserted-by":"crossref","unstructured":"Le QT, Blanchet M, Seidah NG, Labonte P. Plasma Membrane Tetraspanin CD81 Complexes with Proprotein Convertase Subtilisin\/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR), and Its Levels Are Reduced by PCSK9. J Biol Chem 2015;290:23385\u2013400.","DOI":"10.1074\/jbc.M115.642991"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870319303059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870319303059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:04:15Z","timestamp":1757570655000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870319303059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":37,"alternative-id":["S0002870319303059"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2019.11.004","relation":{},"ISSN":["0002-8703"],"issn-type":[{"type":"print","value":"0002-8703"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolocumab treatment in patients with HIV and hypercholesterolemia\/mixed dyslipidemia: BEIJERINCK study design and baseline characteristics","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2019.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}